309 related articles for article (PubMed ID: 32389832)
1. Insights into pharmacological mechanisms of polydatin in targeting risk factors-mediated atherosclerosis.
Ahmad P; Alvi SS; Iqbal D; Khan MS
Life Sci; 2020 Aug; 254():117756. PubMed ID: 32389832
[TBL] [Abstract][Full Text] [Related]
2. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
Sultan Alvi S; Ansari IA; Khan I; Iqbal J; Khan MS
Free Radic Biol Med; 2017 Jul; 108():394-403. PubMed ID: 28412198
[TBL] [Abstract][Full Text] [Related]
3. Keep recycling going: New approaches to reduce LDL-C.
Klein-Szanto AJP; Bassi DE
Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.
Hess CN; Low Wang CC; Hiatt WR
Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667
[TBL] [Abstract][Full Text] [Related]
5. Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.
Waiz M; Alvi SS; Khan MS
EXCLI J; 2022; 21():47-76. PubMed ID: 35221836
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 and atherosclerosis: Looking beyond LDL regulation.
Ragusa R; Basta G; Neglia D; De Caterina R; Del Turco S; Caselli C
Eur J Clin Invest; 2021 Apr; 51(4):e13459. PubMed ID: 33236356
[TBL] [Abstract][Full Text] [Related]
7. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
8. Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits.
Xing WW; Wu JZ; Jia M; Du J; Zhang H; Qin LP
Biomed Pharmacother; 2009 Aug; 63(7):457-62. PubMed ID: 18657948
[TBL] [Abstract][Full Text] [Related]
9. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
10. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
11. Polydatin for treating atherosclerotic diseases: A functional and mechanistic overview.
Wu M; Li X; Wang S; Yang S; Zhao R; Xing Y; Liu L
Biomed Pharmacother; 2020 Aug; 128():110308. PubMed ID: 32480216
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters.
Du J; Sun LN; Xing WW; Huang BK; Jia M; Wu JZ; Zhang H; Qin LP
Phytomedicine; 2009 Jun; 16(6-7):652-8. PubMed ID: 19106037
[TBL] [Abstract][Full Text] [Related]
13. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
15. Polydatin Inhibits NLRP3 Inflammasome in Dry Eye Disease by Attenuating Oxidative Stress and Inhibiting the NF-κB Pathway.
Park B; Jo K; Lee TG; Hyun SW; Kim JS; Kim CS
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31731792
[TBL] [Abstract][Full Text] [Related]
16. Polydatin Attenuates Atherosclerosis in ApoE
Huang Z; Tian G; Cheng S; Zhao D; Zhang Y; Jia Y; Zhou F
Am J Chin Med; 2018; 46(8):1841-1859. PubMed ID: 30537866
[TBL] [Abstract][Full Text] [Related]
17. Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in ApoE
Li F; Zhang T; He Y; Gu W; Yang X; Zhao R; Yu J
J Ethnopharmacol; 2020 Jan; 247():112232. PubMed ID: 31606534
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
19. Polydatin attenuates atherosclerosis in apolipoprotein E-deficient mice: Role of reverse cholesterol transport.
Peng Y; Xu J; Zeng Y; Chen L; Xu XL
Phytomedicine; 2019 Sep; 62():152935. PubMed ID: 31085374
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
Zhou R; Stouffer GA; Smith SC
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
